PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription

Laboratory Investigation

Volumn 89, Issue 3, 2009, Pages 301-314

  Kanteti, Rajani ^a   Nallasura, Vidya ^a   Loganathan, Sivakumar ^a   Tretiakova, Maria ^a,b   Kroll, Todd ^a,b   Krishnaswamy, Soundararajan ^a   Faoro, Leonardo ^a   Cagle, Philip ^c   Husain, Aliya N ^a,b   Vokes, Everett E ^a   Lang, Deborah ^a   Salgia, Ravi ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b University of Chicago   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

c Met inhibition; PAX transcription factors; PAX5; RTK

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR PAX9;

ARTICLE; CANCER CELL CULTURE; CARCINOID; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; ESOPHAGUS CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LIVER CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MESOTHELIOMA; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CANCER; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; CELL NUCLEUS; DNA MUTATIONAL ANALYSIS; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; IN SITU HYBRIDIZATION, FLUORESCENCE; INDOLES; LUNG NEOPLASMS; NEOPLASMS; PAIRED BOX TRANSCRIPTION FACTORS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MET; RNA, SMALL INTERFERING; SMALL CELL LUNG CARCINOMA; SULFONAMIDES;

EID: 61349162234     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.168     Document Type: Article

References (47)

1. Abidoye O, Ferguson MK, Salgia R. Lung carcinoma in African Americans. Nat Clin Pract Oncol 2007;4:118-129.
2. Robson EJD, He S-J, Eccles MR. A panorama of PAX genes in cancer and development. Nat Rev Cancer 2006;6:52-62.
3. Cobaleda C, Schebesta A, Delogu A, et al. Pax5: the guardian of B cell identity and function. Nat Immunol 2007;8:463-470.
4. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998;A92:1308-1316.
5. Kozmik Z, Sure U, Rüedi D, et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci USA 1995;92:5709-5713.
6. Baumann Kubetzko FB, Di Paolo C, Maag C, et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 2004;25:1839-1846.
7. Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep 2007;9:102-108.
8. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the protooncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993;67:37-46.
9. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8:620-627.
10. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996;74:1862-1868.
11. Epstein JA, Shapiro DN, Cheng J, et al. Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci USA 1996;93:4213-4218.
12. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-1488.
13. Fujita N, Wade PA. Use of bifunctional cross-linking reagents in mapping genomic distribution of chromatin remodeling complexes. Methods 2004;33:81-85.
14. Sato Y, Sugie R, Tsuchiya B, et al. Comparison of the DNA extraction methods for polymerase chain reaction amplification from formalin-fixed and paraffin-embedded tissues. Diagn Mol Pathol 2001;10:265-271.
15. French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003;162:1053-1060.
16. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARg1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000;289:1357-1360.
17. Relaix F, Polimeni M, Rocancourt D, et al. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev 2003;17:2950-2965.
18. Gomes DA, Rodrigues MA, Leite MF, et al. c-Met must translocate to the nucleus to initiate calcium signals. J Biol Chem 2008;283: 4344-4351.
19. Pozner-Moulis S, Pappas DJ, Rimm DL. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res 2006;66:7976-7982.
20. Salgia R. c-Met inhibition. Clin Adv Hematol Oncol 2006;4:823-824.
21. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998;92:1308-1316.
22. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999;94:3108-3113.
23. Sica G, Vazquez MF, Altorki N, et al. PAX5 expression in pulmonary neuroendocrine neoplasms: its usefulness in surgical and fine-needle aspiration biopsy specimens. Am J Clin Pathol 2008;129: 556-562.
24. Mhawech-Fauceglia P, Saxena R, Zhang S, et al. PAX5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol 2007;60:709-714.
25. Poleev A, Fickenscher H, Mundlos S, et al. AX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development 1992;116:611-623.
26. Tagge EP, Hanson P, Re GG, et al. Paired box gene expression in Wilms' tumor. J Pediatr Surg 1994;29:134-141.
27. Eccles MR, Yun K, Reeve AE, et al. Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors. Am J Pathol 1995;146:40-45.
28. Bouchard M, Souabni A, Mandler M, et al. Nephric lineage specification by Pax2 and Pax8. Genes Dev 2002;16:2958-2970.
29. Lui WO, Foukakis T, Lidén J, et al. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR (gamma) fusion oncogene. Oncogene 2005;24: 1467-1476.
30. Scouten WT, Patel A, Terrell R, et al. Cytoplasmic localization of the paired box gene, Pax-8, is found in pediatric thyroid cancer and may be associated with a greater risk of recurrence. Thyroid 2004;14:1037-1046.
31. Shapiro DN, Sublett JE, Li B, et al. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 1993;53:5108-5112.
32. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;5:230-235.
33. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;3:113-117.
34. Anderson J, Ramsay A, Gould S, et al. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 2001;159: 1089-1096.
35. Gerber JK, Richter T, Kremmer E, et al. Progressive loss of PAX9 expression correlates with increasing malignancy of dysplastic and cancerous epithelium of the human oesophagus. J Pathol 2002;197:293-297.
36. Poppe B, De Paepe P, Michaux L, et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 2005;44:218-223.
37. Ohno H, Ueda C, Akasaka T. The t (9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2000;36:435-4345.
38. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341.
39. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
40. Ma PC, Schaefer E, Christensen JG, et al. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005;11:2312-2319.
41. Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, et al. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 2007;292: L1488-L1494.
42. Zhang X, Li Y, Dai C, et al. Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney. Am J Physiol Renal Physiol 2003;284:F82-F94.
43. Stuart ET, Haffner R, Oren M, et al. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 1995;14: 5638-5645.
44. Emelyanov AV, Kovac CR, et al. The interaction of Pax5 (BSAP) with Daxx can result in transcriptional activation in B cells. J Biol Chem 2002;277:11156-11164.
45. Miccadei S, Provenzano C, Mojzisek M, et al. Retinoblastoma protein acts as Pax 8 transcriptional coactivator. Oncogene 2005;24: 6993-7001.
46. Park D, Jia H, Rajakumar V, et al. Pax2/5/8 proteins promote cell survival in C. elegans. Development 2006;133:4193-4202.
47. Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007;12:1096-1104.